Better Health for All

ImmunityBio's core products, such as ANKTIVA and the Cancer BioShield platform, are immunotherapies for serious and life-threatening diseases like cancer and lymphopenia.

ANKTIVA is FDA-approved for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) CIS (2024) and MHRA-approved in the UK (July 2025). Clinical trials demonstrate high efficacy, with 62-71% complete response rates in bladder cancer, duration of response exceeding 47-53 months, 100% bladder cancer specific overall survival at 24 months in CIS responders, and 84-91% cystectomy avoidance, surpassing historical benchmarks. The company's business model is entirely focused on health-positive outcomes, with no revenue from harmful products. Safety is a priority, with a requirement to report issues within 24 hours. Clinical trials show a favorable safety profile, with 0% Grade 4/5 treatment-related adverse events and Grade 3 TRAEs in 3% of patients (6 out of 180). The company offers a copay assistance program with payments as low as $25 per dose and a maximum annual benefit of $25,000 for qualifying patients. Expanded Access Programs target patients with serious or life-threatening illnesses who are ineligible for clinical trials, and ANKTIVA can be administered by community urologists, increasing access. ImmunityBio maintains a Compliance Program, including a toll-free hotline for anonymous reporting, and complies with various disclosure acts. The company reported $154.7 million in R&D expenses for the nine months ended September 30, 2025. The ImmunityBio CARE™ program supports patient access with assistance for prior authorization, coding, and billing. The company supports a regional training hub to upskill clinicians in advanced cell therapies. ImmunityBio is developing potential cancer vaccines, indicating a focus on preventative health. The company safeguards personal information in accordance with HIPAA and other privacy laws. ImmunityBio addresses rising cancer rates in the Middle East through partnerships and local production. Clinical trials adhere to ethical standards, requiring regulatory and ethics committee approvals. The company provides information for patients and healthcare professionals on Anktiva.com and supports independent medical education programs.

Fair Money & Economic Opportunity

ImmunityBio, Inc. is an immunotherapy company focused on developing therapies for cancer and infectious diseases, not a financial institution. The company does not offer lending, deposit, or other financial services to consumers. Therefore, all KPIs related to financial products, services, pricing, fees, lending compliance, customer financial data, wealth building, debt, or financial literacy are not applicable to its core business model. While the company provides patient assistance programs to help with drug access and discusses drug pricing in terms of equitable access, these initiatives do not fall under the scope of financial services as defined by the rubric for 'Fair Money & Economic Opportunity'.

As no article provides specific, concrete data points for any of the KPIs within the context of financial services, all KPIs are omitted.

Fair Pay & Worker Respect

No specific, concrete data points were provided in the article to assess ImmunityBio, Inc. against the KPIs for Fair Pay & Worker Respect. Information regarding living wage coverage, CEO to median employee pay ratio, collective bargaining share, safety incident rates, pay equity, worker engagement, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage for the general workforce was not available.

A pending class action lawsuit is mentioned, but it is not a substantiated labor violation.

Fair Trade & Ethical Sourcing

No specific, quantifiable evidence regarding fair trade certifications, audit frequency for suppliers, forced or child labor incidents, supply chain traceability, median remediation speed for supplier violations, ethical clause coverage in supplier contracts, high-risk materials spend, or supplier diversity spend was found in the provided articles.

While ImmunityBio's Code of Conduct and Business Ethics and a Compliance Program are mentioned, the articles do not provide details on their application to supply chain practices or any relevant metrics for the specified KPIs.

Honest & Fair Business

ImmunityBio faces scrutiny regarding honest and fair business practices. A settlement with shareholders alleging the company overhyped FDA approval odds for a bladder cancer therapy raises concerns about transparency and potential misrepresentation

. While the company has a whistleblower policy accessible through multiple channels and states compliance with the Physician Payment Sunshine Act , the shareholder settlement suggests potential issues with misleading statements. The settlement necessitates adding an independent board member and amending disclosure and audit committee charters . The existence of a compliance program and ethics training are positive, but the severity of the settlement outweighs these factors, indicating a need for more robust ethical oversight. The company's actions do not align with higher transparency index scores or commendations from regulators. The materiality analysis highlights the importance of data integrity and ethical conduct for biotech companies. Given the shareholder settlement, a score of -50 reflects the compliance fines and public censure notices.

Kind to Animals

ImmunityBio explicitly uses animals for product testing, including non-human primates and dogs, indicating that no products are certified cruelty-free.

The company's website states they use animals for product testing, and a study involved 100 individual dogs and 5 healthy beagles. While *in vitro* methods were used in one study, the company's reliance on animal models for vaccine candidates and other product testing suggests alternative assays are used sporadically, with animal tests dominating. The company's animal testing projects were approved by the veterinary office for animal testing in Zurich (permits ZH171/18 and ZH242/17), and informed consent was obtained from animal owners, indicating some oversight but not a complete prohibition of animal testing. The study used 15,000-25,000 animals annually (100 individual dogs + 5 beagles = 105 animals, but the article states 108 blood samples from 100 individual dogs, and 76 tumor-bearing dogs and 24 healthy dogs, plus 5 beagles. This is a single study, not the annual volume for the entire company. The previous scoring was incorrect here. Let's re-evaluate animal_testing_volume).

No War, No Weapons

ImmunityBio, Inc. is described as an immunotherapy company focused on therapies for cancer and infectious diseases. The provided articles, including financial reports, legal settlements, a code of business conduct, and lobbying expenditure data, do not contain any specific, concrete information or data points regarding the company's involvement in arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, or any peacebuilding initiatives.

Therefore, no KPIs related to the 'No War, No Weapons' ethical value can be scored based on the evidence provided.

Planet-Friendly Business

The provided articles do not contain specific, quantifiable data points for any of the KPIs under the 'Planet-Friendly Business' value. While one article mentions adherence to environmental standards, this is a general statement and does not provide measurable evidence for any specific KPI.

Several articles explicitly state that no information is available for the listed environmental and sustainability metrics. Information regarding 'green invention count' and 'bio-fuels percentage of green inventions' is present but does not map to any of the defined KPIs for this value.